Next Article in Journal
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
Next Article in Special Issue
B-Myb Is Up-Regulated and Promotes Cell Growth and Motility in Non-Small Cell Lung Cancer
Previous Article in Journal
Analysis of Gene Expression Signatures in Cancer-Associated Stroma from Canine Mammary Tumours Reveals Molecular Homology to Human Breast Carcinomas
Previous Article in Special Issue
Overexpression of Transforming Acidic Coiled Coil‑Containing Protein 3 Reflects Malignant Characteristics and Poor Prognosis of Glioma
Open AccessReview

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, 98125 Messina, Italy
Department of Obstetrics and Gynecology, Campus Bio Medico University of Rome, 00128 Rome, Italy
Unit of Psychodiagnostics and Clinical Psychology, University of Catania, 95124 Catania, Italy
Department of General Surgery and Medical Surgical Specialties, University of Catania, 95124 Catania, Italy
Department of Human Pathology, Unit of Urology, University of Messina, 98124 Messina, Italy
Radiation Oncology Department, AO “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, Italy
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy
Unit of Gynecology and Obstetrics, Desenzano del Garda Hospital, Section of Gavardo, 25085 Gavardo, Brescia, Italy
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Int. J. Mol. Sci. 2017, 18(5), 1100;
Received: 12 March 2017 / Revised: 13 May 2017 / Accepted: 16 May 2017 / Published: 20 May 2017
(This article belongs to the Collection Advances in Molecular Oncology)
Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”, “angiogenesis therapy”, “cancer stem cell therapy”, “prognostic biomarker”, and “novel antibody-drug”. Based on our results, the differential expression and accessibility of epithelial cell adhesion molecule-1 on metastatic/chemotherapy-resistant CS cells in comparison to normal tissues and Human Epidermal Growth Factor Receptor 2 (HER2) open up new possibilities in the field of target therapy. Nevertheless, future investigations are needed to clarify the impact of these new therapies on survival rate and medium-/long-term outcomes. View Full-Text
Keywords: carcinosarcomas; uterine cancer; genetics; epigenetics; immunotherapy carcinosarcomas; uterine cancer; genetics; epigenetics; immunotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Vitale, S.G.; Laganà, A.S.; Capriglione, S.; Angioli, R.; La Rosa, V.L.; Lopez, S.; Valenti, G.; Sapia, F.; Sarpietro, G.; Butticè, S.; Tuscano, C.; Fanale, D.; Tropea, A.; Rossetti, D. Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. Int. J. Mol. Sci. 2017, 18, 1100.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop